Posted by Michael Wonder on 03 Feb 2021
Patients gain early access to Pfizer's atopic dermatitis drug
3 February 2021 - People living in the UK with severe atopic dermatitis are to be given early access to Pfizer's abrocitinib following a green light by the MHRA.
The regulator has issued a positive Early Access to Medicine Scientific (EAMS) opinion allowing patients to be treated with the drug before it is officially licensed.
